ALK阳性大B细胞淋巴瘤的多机构研究:ALK抑制剂与生物学导向治疗时代的结果
这项多机构回顾性研究分析了2002至2024年间美国六家学术中心确诊的39例ALK阳性大B细胞淋巴瘤,患者前线多接受蒽环类化疗,复发时采用生物学导向及非化疗策略;中位随访5.4年,中位无事件生存期0.6年、中位总生存期1.5年,提示化疗获益有限,支持整合生物学靶向治疗。
要点
- 92%患者接受前线蒽环类化疗,43%接受强化方案,15%行前线自体造血干细胞移植,但结局仍差。
- 中位无事件生存期0.6年(95%CI 0.4-0.9),中位总生存期1.5年(95%CI 1.3-NR)。
- 12例接受ALK抑制剂,阿来替尼较克唑替尼显示更持久缓解;来那度胺和免疫检查点抑制剂亦显示活性。
核心结论
- 研究结果突显化疗获益有限,即使强化或后续自体造血干细胞移植亦然,并支持整合生物学靶向治疗,后者可能与本队列较历史结局改善的总生存期有关。
- 需要前瞻性协作研究以更好地理解疾病生物学并明确现代治疗在这类罕见淋巴瘤中的最佳应用。
研究设计与样本
- 多机构回顾性研究,分析2002至2024年间美国六家学术中心确诊的39例ALK阳性大B细胞淋巴瘤病例。
- 治疗包括前线传统细胞毒方案,复发时采用生物学导向及非化疗策略。
主要发现
- 92%患者接受前线蒽环类化疗,43%接受强化方案,15%行前线自体造血干细胞移植。
- 中位随访5.4年,中位无事件生存期0.6年(95%CI 0.4-0.9),中位总生存期1.5年(95%CI 1.3-NR)。
- 1年和5年无事件生存率分别为28%和17%,对应总生存率分别为72%和42%。
- 晚期分期和高IPI评分与较差结局相关。
- 12例接受ALK抑制剂,阿来替尼较克唑替尼显示更持久缓解;来那度胺和免疫检查点抑制剂亦显示活性,包括持久完全缓解;5例接受异基因造血干细胞移植,其中3例达到持续缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma with poor outcomes using standard chemotherapy. In this multi-institutional retrospective study, we analyzed 39 cases of ALK+ LBCL identified at six US academic centers from 2002 to 2024, with treatment including conventional cytotoxic regimens in frontline and biologically informed and nonchemotherapy-based strategies in the relapsed setting. Ninety-two percent of patients received frontline anthracycline-based chemotherapy; 43% received intensified regimens, and 15% underwent upfront autologous stem cell transplantation (ASCT). Despite these approaches, outcomes remained poor. At a median follow-up of 5.4 years, median event-free survival (EFS) was 0.6 years (95% CI, 0.4-0.9), and median overall survival (OS) was 1.5 years (95% CI, 1.3-NR). One- and five-year EFS rates were 28% and 17%, while corresponding OS rates were 72% and 42%, respectively. Advanced stage and high IPI scores were associated with inferior outcomes. Twelve patients received ALK inhibitors, with alectinib showing more durable responses than crizotinib. Lenalidomide and immune checkpoint inhibitors also demonstrated activity, including durable complete responses. Five patients underwent allogeneic stem cell transplantation, with three achieving sustained remission. In conclusion, our findings highlight the limited benefit of chemotherapy, even when intensified or followed by ASCT, and support the integration of biologically targeted therapies, which may have contributed to improved OS in our cohort compared to historical outcomes. Prospective, collaborative studies are needed to better understand disease biology and define optimal use of modern therapies in this rare lymphoma.
引用
- Atallah-Yunes SA, Nze CC, King RL, et al. Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies. Am J Hematol. 2025. PMID: 40899786. doi:10.1002/ajh.70058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。